At 24 h after seeding cells were treated with Cetuximab (ErbituxL, Merck, Darmstadt, Germany; 5 μg/ml; IgG as control), Cisplatin (Teva, Ulm, Germany; 0.1 μM) or Gemcitabine (Medac, Wedel, Germany; 10 nM). After 23 h of incubation, cells were treated with BEMER therapy (~13 μT, 8 min) and irradiated 1 h later as described above. Cetuximab remained in the cell culture medium for the entire growth period, Cisplatin and Gemcitabine treated cells were washed with cell culture medium 48 h after treatment.
Gemcitabine
Manufactured by Medac
Sourced in Germany
Gemcitabine is a synthetic nucleoside analog used as a laboratory reagent. It functions as an antimetabolite, inhibiting DNA synthesis and cell division.
Automatically generated - may contain errors
Lab products found in correlation
Cisplatin, by Teva Pharmaceuticals (1 mentions)
Cetuximab, by Merck Group (1 mentions)
Irinotecan, by Teva Pharmaceuticals (1 mentions)
Irinotecan, by Pfizer (1 mentions)
Oxaliplatin, by Teva Pharmaceuticals (1 mentions)
Paclitaxel, by Teva Pharmaceuticals (1 mentions)
Xtt cell proliferation kit, by Sartorius (1 mentions)
Erlotinib, by Roche (1 mentions)
2 protocols using gemcitabine
1
Combination Therapy with Cetuximab, Cisplatin, and Gemcitabine
2
Chemosensitivity of Ascites-Derived PDAC Cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
2 × 103 ascites-derived PDAC primary cells per well from 14 different patients were seeded in 96-well plates and cultured for 3–4 days. The cells were treated with different chemotherapeutic agents: gemcitabine 10 μM (Medac, Wedel, Germany), erlotinib 10 μM (Roche, Basel, Switzerland), cisplatin 1 μM (Pharma-Chem, Haarlem, Holland), 5FU 5 μM and oxaliplatin 6 μM (Ebewe, Unterach, Austria), irinotecan 10 μM (Hospira, Melbourne, Australia) and paclitaxel 1 μM (Teva, Petach Tikva, Israel) for 72 h. FOLFIRINOX is a combination of 5FU, irinotecan and oxaliplatin. Cell proliferation was measured using the XTT cell proliferation kit (Biological Industries) according to the manufacturer's protocol.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!